{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:09:25Z","timestamp":1767971365344,"version":"3.49.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Liver arteriovenous malformations (AVM) in hereditary hemorrhagic telangiectasia (HHT) can necessitate liver transplantation. There is limited data on HHT patients undergoing liver transplantation (LT) in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Two sources of data were used: (1) Scientific Registry of Transplant Recipients (SRTR) database (1998-2016) (2) Single center liver transplant database (Mayo Clinic Rochester, MN). The aims of this study were (1) to determine trends in LT for HHT-related liver involvement in the United States using the SRTR database; (2) to identify clinical characteristics, indications, and outcomes for LT in HHT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Thirty-nine HHT patients were listed for LT in the SRTR database from 1998-2016 to 1998-2001 (n = 1); 2002-2005 (n = 4); 2006-2010 (n = 10), and 2011-2016 (n = 24). Twenty-four underwent LT at a median age of 47.5 years (interquartile range, 37.0-58.5 years). Median calculated MELD score at time of LT was 8.0 (interquartile range, 7.0-9.5), and 75% received an exception MELD score. Two status-1 patients died during transplant surgery. Nineteen (86%) patients were alive after a median post-LT follow-up of 48 months, whereas 2 patients were lost to follow-up. Five of the aforementioned HHT patients underwent LT at Mayo Clinic, 4 with high output cardiac failure, and 1 with biliary ischemia. All 5 were alive at the time of last follow-up with good graft function and resolution of heart failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Outcomes after LT for HHT patients are excellent with 86% survival after a median follow-up of 48 months and resolution of heart failure. LT listing for HHT has increased in substantially in more recent eras.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002491","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:29:34Z","timestamp":1539908974000},"page":"1418-1424","source":"Crossref","is-referenced-by-count":17,"title":["Liver Transplantation Trends and Outcomes for Hereditary Hemorrhagic Telangiectasia in the United States"],"prefix":"10.1097","volume":"103","author":[{"given":"Vivek N.","family":"Iyer","sequence":"first","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnam","family":"Saberi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Mt. Sinai New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Heimbach","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Larson","sequence":"additional","affiliation":[{"name":"Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Raghavaiah","sequence":"additional","affiliation":[{"name":"BGS Gleneagles Global Hospital, Kengeri, Bangalore, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Ditah","sequence":"additional","affiliation":[{"name":"Digestive Care, Regions Hospital & HealthPartners Specialty Center Minneapolis, University of Minnesota Medical School, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Swanson","sequence":"additional","affiliation":[{"name":"Pulmonology and Critical Care Medicine, Mayo Clinic, Scottsdale, AZ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.","family":"Kamath","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KD","family":"Watt","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timucin","family":"Taner","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Krowka","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Leise","sequence":"additional","affiliation":[{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199510053331407","article-title":"Hereditary hemorrhagic telangiectasia.","volume":"333","author":"Guttmacher","year":"1995","journal-title":"N Engl J Med"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.","volume":"48","author":"Faughnan","year":"2011","journal-title":"J Med Genet"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2036.2008.03775.x","article-title":"Review article: the hepatic manifestations of hereditary haemorrhagic telangiectasia.","volume":"28","author":"Sabba","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJM200009283431305","article-title":"Liver disease in patients with hereditary hemorrhagic telangiectasia.","volume":"343","author":"Garcia-Tsao","year":"2000","journal-title":"N Engl J Med"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0028-1085093","article-title":"Hepatic vascular malformations in hereditary hemorrhagic telangiectasia.","volume":"28","author":"Khalid","year":"2008","journal-title":"Semin Liver Dis"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/0168-8278(95)80455-2","article-title":"Liver transplantation for hepatic arteriovenous malformation in hereditary haemorrhagic telangiectasia.","volume":"22","author":"Bauer","year":"1995","journal-title":"J Hepatol"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0016-5085(99)70243-X","article-title":"Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement.","volume":"116","author":"Boillot","year":"1999","journal-title":"Gastroenterology"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/lt.21990","article-title":"Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study.","volume":"16","author":"Dupuis-Girod","year":"2010","journal-title":"Liver Transpl"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/lt.20463","article-title":"Liver transplantation for cardiac failure in patients with hereditary hemorrhagic telangiectasia.","volume":"11","author":"Thevenot","year":"2005","journal-title":"Liver Transpl"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.transproceed.2007.05.022","article-title":"The role of liver transplantation in the treatment of hereditary hemorrhagic telangiectasia: a short literature review.","volume":"39","author":"Scelzo","year":"2007","journal-title":"Transplant Proc"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0952-8180(00)00160-4","article-title":"Liver transplantation for hepatic arteriovenous malformation with high-output cardiac failure in hereditary hemorrhagic telangiectasia: hemodynamic study.","volume":"12","author":"Le Corre","year":"2000","journal-title":"J Clin Anesth"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00007890-200107270-00012","article-title":"Liver transplantation for treatment of intrahepatic Osler\u2019s disease: first experiences.","volume":"72","author":"Pfitzmann","year":"2001","journal-title":"Transplantation"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1053\/jlts.2001.21313","article-title":"Hepatic involvement in hereditary hemorrhagic telangiectasia: an unusual indication for liver transplantation.","volume":"7","author":"Hillert","year":"2001","journal-title":"Liver Transpl"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/lt.500040609","article-title":"Liver transplantation as definitive therapy for complications after arterial embolization for hepatic manifestations of hereditary hemorrhagic telangiectasia.","volume":"4","author":"Odorico","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/01.sla.0000247258.35406.a4","article-title":"Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European Liver Transplant Registry.","volume":"244","author":"Lerut","year":"2006","journal-title":"Ann Surg"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.hpb.2017.03.005","article-title":"Liver transplantation for hereditary hemorrhagic telangiectasia: a systematic review.","volume":"19","author":"Felli","year":"2017","journal-title":"HPB (Oxford)"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1002\/lt.20978","article-title":"Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia.","volume":"12","author":"Garcia-Tsao","year":"2006","journal-title":"Liver Transpl"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/lt.21417","article-title":"Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.","volume":"14","author":"Mitchell","year":"2008","journal-title":"Liver Transpl"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"e1966","DOI":"10.1097\/MD.0000000000001966","article-title":"Bevacizumab to treat cholangiopathy in hereditary hemorrhagic telangiectasia: be cautious: a case report.","volume":"94","author":"Maestraggi","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10456-017-9585-2","article-title":"Executive summary of the 12th HHT international scientific conference.","volume":"21","author":"Andrejecsk","year":"2018","journal-title":"Angiogenesis"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1002\/ajh.24878","article-title":"Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in hereditary hemorrhagic Telangiectasia.","volume":"92","author":"Chavan","year":"2017","journal-title":"Am J Hematol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-201907000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:27:49Z","timestamp":1696224469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201907000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002491","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}